全文获取类型
收费全文 | 576篇 |
免费 | 33篇 |
国内免费 | 24篇 |
专业分类
儿科学 | 27篇 |
妇产科学 | 4篇 |
基础医学 | 30篇 |
口腔科学 | 8篇 |
临床医学 | 78篇 |
内科学 | 196篇 |
皮肤病学 | 6篇 |
神经病学 | 22篇 |
特种医学 | 46篇 |
外科学 | 74篇 |
综合类 | 45篇 |
预防医学 | 44篇 |
眼科学 | 6篇 |
药学 | 28篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 1篇 |
2022年 | 5篇 |
2021年 | 2篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 6篇 |
2017年 | 11篇 |
2016年 | 6篇 |
2015年 | 12篇 |
2014年 | 21篇 |
2013年 | 25篇 |
2012年 | 20篇 |
2011年 | 26篇 |
2010年 | 19篇 |
2009年 | 19篇 |
2008年 | 22篇 |
2007年 | 32篇 |
2006年 | 24篇 |
2005年 | 22篇 |
2004年 | 18篇 |
2003年 | 16篇 |
2002年 | 19篇 |
2001年 | 25篇 |
2000年 | 16篇 |
1999年 | 21篇 |
1998年 | 25篇 |
1997年 | 20篇 |
1996年 | 24篇 |
1995年 | 12篇 |
1994年 | 22篇 |
1993年 | 16篇 |
1992年 | 11篇 |
1991年 | 10篇 |
1990年 | 6篇 |
1989年 | 11篇 |
1988年 | 19篇 |
1987年 | 8篇 |
1986年 | 10篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有633条查询结果,搜索用时 15 毫秒
101.
102.
103.
CG Teo 《Oral diseases》2002,8(S2):88-90
Oral hairy leukoplakia (OHL) and Kaposi's sarcoma (KS) are commonly encountered in the HIV-infected patient. A unique feature of OHL is non-cytolytic high level of replication of Epstein–Barr virus (EBV) in the glossal epithelium. The expression of viral-encoded anti-apoptotic proteins concomitant to replicative proteins probably underlies this phenomenon. The question of whether OHL arises from activation of EBV latent in the tongue, or from superinfection by endogenous EBV shed via non-glossal sites or by exogenous EBV remains unresolved. Human herpesvirus 8 (HHV8) is now seen as necessary but not sufficient cause of KS. Expression of HHV8-encoded oncogenic proteins in endothelial cells probably explains the aberrant proliferation of these cells in KS lesions. Studies into why KS is so commonly observed at the palate in HIV-infected patients may provide important clues to its pathogenesis. 相似文献
104.
105.
Judith de Vos-Geelen Sandra ME Geurts Margreet van Putten Liselot BJ Valkenburg-van Iersel Heike I Grabsch Nadia Haj Mohammad Frank JP Hoebers Chantal V Hoge Paul M Jeene Evelien JM de Jong Hanneke WM van Laarhoven Tom Rozema Marije Slingerland Vivianne CG Tjan-Heijnen Grard AP Nieuwenhuijzen Valery EPP Lemmens 《World journal of gastroenterology : WJG》2019,25(47):6835-6846
BACKGROUND The management of proximal esophageal cancer differs from that of tumors located in the mid and lower part of the esophagus due to the close vicinity of vital structures. Non-surgical treatment options like radiotherapy and definitive chemoradiation(CRT) have been implemented. The trends in(non-)surgical treatment and its impact on overall survival(OS) in patients with proximal esophageal cancer are unclear, related to its rare disease status. To optimize treatment strategies and counseling of patients with proximal esophageal cancer,it is therefore essential to gain more insight through real-life studies.AIM To establish trends in treatment and OS in patients with proximal esophageal cancer.METHODS In this population-based study, patients with proximal esophageal cancer diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry. The proximal esophagus consists of the cervical esophagus and the upper thoracic section, extending to 24 cm from the incisors. Trends in radiotherapy, chemotherapy, and surgery, and OS were assessed. Analyses were stratified by presence of distant metastasis. Multivariable Cox proportional hazards regression analyses was performed to assess the effect of period of diagnosis on OS, adjusted for patient, tumor, and treatment characteristics.RESULTS In total, 2783 patients were included. Over the study period, the use of radiotherapy, resection, and CRT in non-metastatic disease changed from 53%,23%, and 1% in 1989-1994 to 21%, 9%, and 49% in 2010-2014, respectively. In metastatic disease, the use of chemotherapy and radiotherapy increased over time. Median OS of the total population increased from 7.3 mo [95% confidence interval(CI): 6.4-8.1] in 1989-1994 to 9.5 mo(95%CI: 8.1-10.8) in 2010-2014(logrank P 0.001). In non-metastatic disease, 5-year OS rates improved from 5%(95%CI: 3%-7%) in 1989-1994 to 13%(95%CI: 9%-17%) in 2010-2014(logrank P 0.001). Multivariable regression analysis demonstrated a significant treatment effect over time on survival. In metastatic disease, median OS was 3.8 mo(95%CI:2.5-5.1) in 1989-1994, and 5.1 mo(95%CI: 4.3-5.9) in 2010-2014(logrank P = 0.26).CONCLUSION OS significantly improved in non-metastatic proximal esophageal cancer, likely to be associated with an increased use of CRT. Patterns in metastatic disease did not change significantly over time. 相似文献
106.
107.
108.
109.
110.
Clinimetrics and psychometrics, two accepted methods for developing multiitem health measurement scales, have fundamentally different aims and methods that have seldom been compared and never prospectively. The purpose of this study was to determine whether these two methodologies provided comparable scales in the development of an upper extremity disability measure. Psychometric analysis involved field testing a 70-item questionnaire on 407 patients. Equidiscriminatory item total correlation (EITC) was used to select the top 30 items. Clinimetric testing used the mean importance and severity ratings of the 70 items by 76 patients to select the top 30 items. Clinimetric and psychometric analyses were performed independently. Cronbach's alpha was 0.97 for the top 30 items selected by EITC and 0.96 for the items selected based on patient's ratings. The two scales (after clinician modification to improve face validity) shared 16 items in common (P=0.10). The intraclass correlation coefficient of the patient scores on the two 30-item scales was 0.93 before clinician input and 0.97 after. The mean (and standard deviation) difference between scales was 9.1 (8.8) before and 1.7 (5.2) after clinician input. A scale developed with a clinimetric strategy can measure a complex (so-called heterogeneous) clinical phenomenon (thought to be composed of several patient attributes) but still fulfill psychometric criteria for "homogeneity." Thus, these strategies for the development of health measurement scales, which have been considered potentially opposite or conflicting, may be complementary. 相似文献